160882-30-4

Usage

Functional groups

Benzimidazole ring
Carbonyl group
Chloride group

Applications

Building block in organic synthesis
Pharmaceutical industry for drug synthesis
Synthesis of benzimidazole derivatives
Key intermediate in antiparasitic and antifungal agents

Reactivity

Reactive acylating agent
Used in the preparation of benzimidazole derivatives

Biological activities

Diverse biological activities in benzimidazole derivatives

Additional uses

Potential corrosion inhibitor for metals in acidic media

Safety precautions

Handle with care due to reactivity and potential health hazards

Upstream product

• 15788-16-6 1H-benzimidazole-6-carboxylic acid 
• 619-05-6 3,4-diaminobenzoic acid 
• 15788-16-6 5-benzimidazolecarboxylic acid 

Downstream Products

• 1027255-49-7 (S)-N-(3-(1-(6-chloropyrazin-2-ylamino)ethyl)phenyl)-1H-benzo[d]imidazole-6-carboxamide 
• 58442-16-3 5-Acetylbenzimidazol 

Relevant academic research and scientific papers

Homology modelling, molecular dynamics simulation and docking evaluation of β-tubulin of Schistosoma mansoni

Schistosomiasis is one of the neglected diseases causing considerable morbidity and mortality throughout the world. Microtubules with its main component, tubulin play a vital role in helminthes including schistosomes. Benzimidazoles represent potential drug candidates by binding β-tubulin. The study aimed to generate a homology model for the β-tubulin of S. mansoni using the crystal structure of O vis aries (Sheep) β-tubulin (PDB ID: 3N2G D) as a template, then different β-tubulin models were generated and two previously reported benzimidazole derivatives (NBTP-F and NBTP-OH) were docked to the generated models, the binding results indicated that both S. mansoni, S. haematobium were susceptible to the two NBTP derivatives. Additionally, three mutated versions of S. mansoni β-tubulin wild-type were generated and the mutation (F185Y) seems to slightly enhance the ligand binding. Dynamics simulation experiments showed S. haematobium β-tubulin is highly susceptible to the tested compounds; similar to S. mansoni, moreover, mutated models of S. mansoni β-tubulin altered its NBTPs susceptibility. Moreover, additional seven new benzimidazole derivatives were synthesized and tested by molecular docking on the generated model binding site of S. mansoni β-tubulin and were found to have good interaction inside the pocket.

Anticoagulated small-molecule compound, application thereof and drug including compound

The invention relates to an anticoagulated small-molecule compound, application thereof and a drug including the compound. A structural formula of the anticoagulated small-molecule compound is shown in the description, and the anticoagulated small-molecul

Synthesis and biological evaluation of heteroarylnonanenitriles as potential antitrypanosomal agents: Serendipitous discovery of novel anticholinesterase hits

We have recently developed three antitrypanosomal leads that feature a unit of huprine or (6-chloro-)tacrine linked to a 8-cyanooctyl side chain, which, unfortunately, exhibit very potent (low nanomolar) acetylcholinesterase (AChE) inhibitory activity, which might lead to unwanted cholinergic side-effects. Because huprine and tacrine moieties impart high acetylcholinesterasic potency, we have explored their replacement by alternative heteroaromatic systems (thiazolylbenzamido, quinoxalinecarboxamido, benzimidazolecarboxamido, and benzothiazolylamino moieties), while retaining the 8- cyanooctyl side chain. These structural modifications led to the desired drop in AChE inhibitory activity (low micromolar), albeit at the expense of the antitrypanosomal potency. However, despite the lower AChE inhibitory activity of the novel compounds compared to that of the initial leads, their potency is comparable to that of some AChE inhibitors currently approved for Alzheimer’s disease (AD) treatment. They are brain permeable and less lipophilic than the leads, thereby emerging as interesting novel hits for future AChE inhibitor-based AD drug discovery programs.

INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

High temperature proton exchange membranes based on poly(arylene ether)s with benzimidazole side groups for fuel cells

A new benzimidazole containing monomer has been synthesized for the preparation of poly(arylene ether sulfone) (PAES) and poly(arylene ether benzimidazole) (PAEB) with benzimidazole side groups by nucleophilic substitution polymerization. PAES and PAEB had inherent viscosities of 0.56 and 0.93 dL g-1, respectively, measured in N,N-dimethylacetamide (DMAc) at a concentration of 0.5 g dL-1. The structures of the benzimidazole containing monomer, PAES and PAEB were characterized by FTIR, 1H NMR, and elemental analyses. These polymers showed excellent solubility in common organic solvents, such as DMAc, dimethyl sulfoxide (DMSO), and N-methyl-pyrrolidinone (NMP) at room temperature. Due to the strong intermolecular hydrogen bonding from the amide and imidazole groups in the side chains, PAES and PAEB had unusually high Tgs at 374 and 381 °C, respectively. The 5% weight loss temperatures of PAES and PAEB were around 472 and 522 °C in air, respectively. The phosphoric acid doping levels of PAES and PAEB membranes were 5.6 and 15.3. The proton conductivity of phosphoric acid doped membranes increased with increasing temperatures and reached to a range of 10-3 to 10-2 S cm-1 at 160 °C. The Royal Society of Chemistry.

HETERO COMPOUND

[Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P1 a

CYANOFLUOROPYRROLIDINE DERIVATIVE

A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions capable of being improved by inhibition of dipeptidyl peptidase IV (DPPIV), diabetes mellitus, immune diseases and the like: [wherein A represents a hydrogen atom or a fluorine atom, R1 and R2 are as defined in the specification, X represents a single bond or a C1-3 alkylene group, and R3 represents a group represented by the formula: -N(R4)COR5, -N(R4)SO2R5, -NR4R6, -SO2R5, -SO2NR4R5, -OCONR4R5, -CH=CH-R7 or -C≡C-R7, or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring or a 9- to 11-membered condensed ring thereof (wherein the heteroaryl group may be substituted with one or more substituents selected from the substituent Y3 group)].

AZOLE-BASED KINASE INHIBITORS

A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating kinase-associated disease states using the compound of formula (I) is also desc